All News
Filter News
Found 660 articles
-
Vir Biotechnology Announces Multiple Abstracts Highlighting New Chronic Hepatitis B and Hepatitis Delta Data Accepted for Presentation at AASLD’s The Liver Meeting® 2023
10/11/2023
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that eight abstracts highlighting new data from its chronic hepatitis B (CHB) and chronic hepatitis delta (CHD) clinical programs have been accepted for presentation at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting ® , taking place in Boston, MA, from November 10-14, 2023.
-
Alnylam Announces Receipt of Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
10/9/2023
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) in response to the Company’s supplemental New Drug Application (sNDA) for patisiran for the treatment of the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis.
-
Alnylam to Present Additional Data for Patisiran in Patients With the Cardiomyopathy of ATTR Amyloidosis
10/6/2023
Alnylam Pharmaceuticals, Inc. today announced that the Company will present new results for patisiran, an investigational RNAi therapeutic in development for the treatment of the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis, at the Heart Failure Society of America (HFSA) Annual Scientific Meeting (ASM) 2023, October 6-9, 2023.
-
Vir Biotechnology to Provide Business Update and Report Third Quarter 2023 Financial Results on November 2, 2023
10/5/2023
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the third quarter ended September 30, 2023, on November 2, 2023.
-
Vir Biotechnology Awarded BARDA Funding to Support Development of Antibody Platform Technologies for Global Infectious Disease Threats
10/3/2023
Vir Biotechnology, Inc. announced that the Biomedical Advanced Research and Development Authority, part of the U.S. Department of Health and Human Services’ Administration for Strategic Preparedness and Response, has awarded Vir approximately $50 million in new funding to advance the development of novel monoclonal antibody candidates and delivery solutions to widen the applicability of mAbs in COVID-19 and in pandemic preparedness and response.
-
UCSF QBI, University College London, and Mount Sinai Identify Shared Molecular Mechanisms Across SARS-CoV-2 Variants that Allow Virus to Thrive Despite Vaccination
9/21/2023
In a study published online in CELL , scientists at UCSF QBI, University College London and the Icahn School of Medicine at Mount Sinai reported breakthrough findings on convergent evolutionary mechanisms shared by COVID-19 variants, allowing them to overcome both adaptive and innate immune system barriers.
-
Vir Biotechnology Announces First Participant Dosed in New Phase 1 Trial Evaluating VIR-1388, an Investigational T Cell Vaccine for the Prevention of HIV
9/20/2023
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the first participant has been dosed in a Phase 1 trial evaluating the safety, reactogenicity and immunogenicity of VIR-1388, an investigational novel T cell vaccine for the prevention of human immunodeficiency virus (HIV).
-
Pliant Therapeutics Appoints Minnie Kuo as Chief Development Officer
9/15/2023
Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced the appointment of Ms. Minnie Kuo as Chief Development Officer.
-
Alnylam Announces Positive Outcome of FDA Advisory Committee Meeting on Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
9/13/2023
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) today announced the positive outcome of the U.S. Food and Drug Administration’s (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC) meeting to discuss the supplemental New Drug Application (sNDA) for patisiran, an investigational RNAi therapeutic in development for the treatment of the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis.
-
Alnylam Stock Trading Halted Today; FDA Advisory Committee to Review Supplemental New Drug Application for Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
9/13/2023
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that NASDAQ has halted trading of the Company’s common stock.
-
Alnylam Reports Positive Topline Results from KARDIA-1 Phase 2 Dose-Ranging Study of Zilebesiran, an Investigational RNAi Therapeutic in Development to Treat Hypertension in Patients at High Cardiovascular Risk
9/7/2023
Alnylam Pharmaceuticals, Inc. Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the KARDIA-1 Phase 2 study of zilebesiran, an investigational RNAi therapeutic targeting liver-expressed angiotensinogen (AGT) in development for the treatment of hypertension.
-
VBI Vaccines Partner Brii Biosciences Announces Topline Interim Results of Phase 2 Study Evaluating BRII-179 (VBI-2601) in Combination With PEG-IFNα for the Treatment of Chronic Hepatitis B
9/6/2023
VBI Vaccines Inc. announced topline cohort-level unblinded Week 36 data from interim analysis of a randomized, placebo-controlled and double-blinded Phase 2 study of BRII-179 (VBI-2601), a first-in-class Pre-S1/Pre-S2/S therapeutic vaccine, in combination treatment with pegylated interferon-alpha (PEG-IFNα) in chronic hepatitis B virus (HBV) patients compared with PEG-IFNα only treatment.
-
Brii Biosciences Announces Topline Interim Results of Phase 2 Study Evaluating BRII-179 (VBI-2601) in Combination with PEG-IFNα for the Treatment of Chronic Hepatitis B
9/6/2023
Brii Biosciences Limited announced topline cohort-level unblinded Week 24 and Week 36 data from interim analysis of a randomized, placebo-controlled and double-blinded Phase 2 study of BRII-179, a first-in-class Pre-S1/Pre-S2/S therapeutic vaccine, in combination treatment with pegylated interferon-alpha in patients with chronic hepatitis B compared with PEG-IFNα only treatment.
-
Vir Biotechnology to Participate in Upcoming September 2023 Investor Healthcare Conferences
8/29/2023
Vir Biotechnology, Inc. announced that management will be participating in the following upcoming investor conferences during the month of September.
-
Brii Biosciences Provides Corporate Updates and Reports 2023 Interim Results
8/22/2023
Brii Biosciences Limited ("Brii Bio," "we," or the "Company," stock code: 2137.HK), a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet need, today announced a corporate update and reported its interim results for the first six months ended June 30, 2023.
-
Personalized Medicine Market Report Insight to 2030
8/9/2023
The global personalized medicine market size was exhibited at USD 2.12 trillion in 2021 and it is expected to be worth around USD 5.7 trillion by 2030 with a CAGR of 11.6% from 2022 to 2030.
-
Alnylam Pharmaceuticals Reports Second Quarter 2023 Financial Results and Highlights Recent Period Activity
8/3/2023
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the second quarter ended June 30, 2023 and reviewed recent business highlights.
-
Xencor Reports Second Quarter 2023 Financial Results
8/3/2023
Xencor, Inc. reported financial results for the second quarter ended June 30, 2023 and provided a review of recent business and clinical highlights.
-
Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2023 Financial Results
8/3/2023
Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the second quarter ended June 30, 2023.
-
Vir Biotechnology to Provide Business Update and Report Second Quarter 2023 Financial Results on August 3, 2023
7/26/2023
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the second quarter ended June 30, 2023 on August 3, 2023.